Janux Therapeutics (JANX) Current Assets (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• On a quarterly basis, Current Assets fell 2.08% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 2.08% decrease from a year earlier, with the FY2025 full-year figure at $975.9 million, down 5.59% from the prior year.
• Current Assets for Q1 2026 stood at $1.0 billion, up from $975.9 million in the prior quarter.
• Over the last five years, Current Assets for JANX reached as high as $1.0 billion in Q4 2024 and fell as low as $309.3 million in Q2 2023.
• Historically, Current Assets has averaged $632.9 million across 5 years, with a median of $658.7 million in 2024.
• Across the five-year window, Current Assets dropped 13.62% in 2023 and surged 195.97% in 2024, its largest moves.
• Year by year, Current Assets stood at $332.4 million in 2022, then climbed by 5.05% to $349.2 million in 2023, then jumped by 195.97% to $1.0 billion in 2024, then decreased by 5.59% to $975.9 million in 2025, then rose by 2.68% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.0 billion in Q1 2026, $975.9 million in Q4 2025, and $998.1 million in Q3 2025.